Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$-0.34 → $-0.34 · observed estimates
NeuroOne Medical Technologies Corp (NMTC)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$0.86-9.37%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NMTC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
No new material legal or audit issues arise | A supporting condition in NeuroOne Medical Technologies Corp's published investment case. The stated target is No new negative legal or audit events. | Under Pressure | New material legal or audit issues reported | Audit issue reported vs no new issues Audit Committee determined non-reliance on Q1 2026 financial statements on May 21, 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$-0.34 → $-0.34 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk medical-device growth story, not yet a proven compounder, because it remains loss-making. The multi-year view is supported by progress in product revenue and international readiness, while recent results leave the thesis in a watch state.
The valuation model describes NMTC as cheap versus peers, with a negative expectations gap, though model confidence is low. The priced-in assessment is tagged justified, and no fragility gates fired, so the evidence does not point to unusually fragile expectations.
Near term, earnings risk is elevated after two recent misses and a reported risk of another miss; financial performance remains weak. On the multi-year view, management is on track with its fiscal 2026 product-revenue goal, OneRF commercialization, and ISO certification, while the broader healthcare backdrop has improved.
The next call matters: a guidance cut would add to the recent execution concerns. The thesis also depends on OneRF adoption and international expansion translating into sustained growth, while weaker job growth could pressure cyclical healthcare names; continued strength from sector bellwethers would support the backdrop.
Over the next 1 to 3 years, NMTC has credible commercialization milestones but remains a loss-making, high-risk business with weak recent performance and a meaningful near-term earnings concern. The long-term thesis hinges on turning product growth and regulatory progress into more reliable financial execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in NeuroOne Medical Technologies Corp's published investment case. The stated target is EPS loss narrows toward -$0.51 next fiscal year. |
| Improving |
| EPS loss worsens beyond -$0.51 in FY27 |
Diluted EPS: $-0.28 per share FY2026-Q3; GAAP. Published target: EPS loss narrows toward -$0.51 next fiscal year. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-0.28 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reach $2.4M product revenue in Q2 2026 | A supporting condition in NeuroOne Medical Technologies Corp's published investment case. The stated target is >=2.4 USD_MILLIONS. | Broken | Q2 revenue falls below $2.4M | Product revenue: $33,748 FY2022-Q1; reported segment. Published target: >=2.4 USD_MILLIONS. The stored target says 2026-Q2; this source reports FY2022-Q1. Fiscal/calendar alignment needs review. Feb 14, 202233,748 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve at least $10.5M revenue in fiscal 2026 | A primary condition in NeuroOne Medical Technologies Corp's published investment case. The stated target is >=10.5 USD_MILLIONS. | Broken | Revenue falls below $10.5M in fiscal 2026 | Revenue: $1.973M FY2026-Q3; GAAP. Published target: >=10.5 USD_MILLIONS. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 20261,973,105 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $-0.34 | $18,192,417 | 2 / 2 |
| 2026-10-02 | $-0.34 | $18,192,417 | 2 / 2 |
| 2026-10-03 | $-0.34 | $18,192,417 | 2 / 2 |
| 2026-10-04 | $-0.34 | $18,192,417 | 2 / 2 |
| 2026-10-05 | $-0.34 | $18,192,417 | 2 / 2 |
| 2026-10-06 | $-0.34 | $18,192,417 | 2 / 2 |
| 2026-10-07 | $-0.34 | $18,192,417 | 2 / 2 |
| 2026-10-08 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-09 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-10 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-11 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-12 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-13 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-14 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-15 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-16 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-17 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-18 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-19 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-20 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-21 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-22 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-23 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-24 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-25 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-26 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-27 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-28 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-29 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-30 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-10-31 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-11-01 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-11-02 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-11-03 | $-0.34 | $18,192,449 | 2 / 2 |
| 2026-11-04 | $-0.34 | $18,192,449 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Dec 15, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.